Kalytera Therapeutics Announces Encouraging Results of a Phase …

VANCOUVER, British Columbia, Feb. 22, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the safety and efficacy of cannabidiol (“CBD”), a primary constituent of the marijuana plant, for the treatment of acute (Grade 3-4) Graft versus Host Disease (“GvHD”).

In the present study, ten patients with acute (Grade 3-4) GvHD that was refractory to standard treatment with high-dose steroids, were administered daily doses of CBD for up to three months. Nine of the ten patients enrolled in the study responded to treatment; seven achieved complete remission, and two achieved a near-complete response. Six patients are still alive with a median follow-up period of 13 months (range 5-30 months). Two patients (one with Grade 3 GvHD and one with Grade 4 GvHD) died from leukemia relapse, and two patients (one with Grade 3 GvHD and one

... read more at: https://www.ptcommunity.com/wire/kalytera-therapeutics-announces-encouraging-results-phase-2a-clinical-study-treatment-acute

by